Holen Sie sich die Stockscreener-App
2.01
4.69%
0.09
Handel nachbörslich:
2.04
0.03
+1.49%
Schlusskurs vom Vortag:
$1.92
Offen:
$1.9
24-Stunden-Volumen:
1.22M
Relative Volume:
1.03
Marktkapitalisierung:
$419.94M
Einnahmen:
$889.00K
Nettoeinkommen (Verlust:
$-156.28M
KGV:
-3.8162
EPS:
-0.5267
Netto-Cashflow:
$-150.06M
1W Leistung:
+9.84%
1M Leistung:
+23.31%
6M Leistung:
-18.29%
1J Leistung:
-12.61%
1-Tages-Spanne:
$1.89
$2.09
1-Wochen-Bereich:
$1.7807
$2.09
52-Wochen-Spanne:
$1.30
$3.4799
Prokidney Corp Stock (PROK) Company Profile
Firmenname
Prokidney Corp
Sektor
Branche
Telefon
336-999-7028
Adresse
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
2.01 | 296.68M | 889.00K | -156.28M | -150.06M | -0.5267 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-30 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-30 | Eingeleitet | JP Morgan | Neutral |
| 2024-09-10 | Eingeleitet | Guggenheim | Buy |
| 2024-03-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-07-25 | Eingeleitet | BTIG Research | Buy |
| 2022-12-21 | Eingeleitet | Jefferies | Buy |
| 2022-11-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-10-18 | Eingeleitet | UBS | Buy |
| 2022-10-14 | Eingeleitet | Citigroup | Buy |
| 2022-09-23 | Eingeleitet | BofA Securities | Buy |
| 2022-09-02 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Prokidney Corp Aktie (PROK) Neueste Nachrichten
ProKidney (NASDAQ:PROK) Stock Price Up 7.6%Should You Buy? - MarketBeat
ProKidney Corp (PROK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
3 Promising Penny Stocks With Market Caps Larger Than $200M - simplywall.st
Keep An Eye On ProKidney As Insider Stock Selling Hits US$3.0m - 富途牛牛
ProKidney (PROK) EPS and Revenue: Headline Results Are Close to Consensus; Post-Earnings: The Stock Closes Near UnchangedBanking Earnings Report - vinanet.vn
ProKidney director Brian Pereira sells $1.07 million in shares By Investing.com - Investing.com Canada
ProKidney director Brian Pereira sells $1.07 million in shares - Investing.com
ProKidney (PROK) Quarter in Focus: The Available Figures Are Largely in Line; Post-Report: Shares Fall 4.05% in the Latest ReadingGuidance Update - vinanet.vn
Brian Jg Pereira Sells 229,338 Shares of ProKidney (NASDAQ:PROK) Stock - MarketBeat
ProKidney (NASDAQ:PROK) Director Sells 222,949 Shares - MarketBeat
Prokidney Insider Sold Shares Worth $1,067,773, According to a Recent SEC Filing - marketscreener.com
ProKidney Director Sold Shares Worth Over $1.0M - TradingView
ProKidney (PROK) director sells 757K shares over 3 days - Stock Titan
ProKidney (PROK) Close: Ends Higher by 3.99% at $1.44 at the Close; Immediate View: Support at $1.37 and Resistance at $1.51 Frame the Range under the Current SnapshotHigh Beta Stocks - dars.gov.et
ProKidney (NASDAQ: PROK) director plans new restricted stock sale - Stock Titan
ProKidney (NASDAQ: PROK) director plans sale after trust offloads 229K - Stock Titan
ProKidney (PROK) Latest Reading: Moves 0.71% Lower to $1.39 in the Current Update; Range Context: the Near-Term Reference Band Stretches From $1.32 to $1.46 in Latest TradingFibonacci Entry Signals - vinanet.vn
ProKidney (PROK) Earnings Comparison: Results Show Limited Variance From Forecasts in the Latest Session; Market Follow-Through: The Market Price Declines 0.36% on the DayPost-Earnings Reaction - vinanet.vn
ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade) (PROK) - Seeking Alpha
PROK Q1 2026 Earnings: Narrow EPS Beat Overshadowed by 5% Stock DeclineEarnings Volatility Report - vinanet.vn
What is HC Wainwright's Estimate for ProKidney Q3 Earnings? - MarketBeat
ProKidney Corp. (PROK) Slides 9.3% to $1.46 as Key Support Level Comes into FocusVolume Breakout Ideas - dars.gov.et
Morgan Stanley (PROK) filings show ProKidney stake at 4.7% and below 5% level - Stock Titan
ProKidney (PROK) Gets a Buy from Guggenheim - The Globe and Mail
ProKidney FY2030 EPS Estimate Decreased by HC Wainwright - MarketBeat
ProKidney reports larger second-quarter loss as key clinical trial expenses mount - Winston-Salem Journal
ProKidney earnings missed, revenue topped estimates By Investing.com - Investing.com Nigeria
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila Times
ProKidney earnings missed, revenue topped estimates - Investing.com
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
ProKidney completes Phase 3 PROACT 1 accelerated approval enrollment - scanx.trade
ProKidney (NASDAQ:PROK) Releases Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
ProKidney reports Q2 revenue of $150,000 as PROACT 1 advances - Quiver Quantitative
Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise - TradingView
PROK: Completed key Phase 3 trial enrollment; cash supports operations into mid-2027 - TradingView
ProKidney Corp. (NASDAQ: PROK) warns on cash runway after $89M H1 loss - Stock Titan
ProKidney Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ProKidney Announces Q2 2026 Financial Results Highlighting Increased Losses and R&D Spending - Kalkine Media
ProKidney Corp (PROK) Stock News Today - TradingKey
PROK Q1 2026 Earnings: Slight EPS Beat Signals Discipline as Clinical Pipeline Drives ValueOne-Time Gain Impact - vinanet.vn
ProKidney Corp. (PROK) director converts paired units into Class A stock - Stock Titan
3 Promising Penny Stocks With Market Caps Under $500M - simplywall.st
PROK Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
ProKidney (PROK) to Release Quarterly Earnings on Tuesday - marketbeat.com
ProKidney Corp. Revenue Breakdown – NASDAQ:PROK - TradingView
ProKidney Corp (PROK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ProKidney (PROK) Climbs 2.6% to $1.58 as Renal Biotech Tests Key Technical LevelsTriple Bottom - vinanet.vn
ProKidney Corp (PROK) Income Statement - TradingKey
ProKidney Corp (PROK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PROK|ProKidney Corp|Price:1.565|Chg%:+0.025 - TradingKey
ProKidney Corp (PROK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Finanzdaten der Prokidney Corp-Aktie (PROK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):